首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin
【24h】

IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin

机译:IL-33增强物质P诱导的人肥大细胞分泌VEGF并在牛皮癣皮肤中增加

获取原文
获取原文并翻译 | 示例
           

摘要

The peptide substance P (SP) has been implicated in inflammatory conditions, such as psoriasis, where mast cells and VEGF are increased. A relationship between SP and VEGF has not been well studied, nor has any interaction with the proinflammatory cyto-kines, especially IL-33. Here we report that SP (0.1-10 μM) induces gene expression and secretion of VEGF from human LAD2 mast cells and human umbilical core blood-derived cultured mast cells (hCBMCs). This effect is significantly increased by coadministration of IL-33 (5-100 ng/mL) in both cell types. The effect of SP on VEGF release is inhibited by treatment with the NK-1 receptor antagonist 733,060. SP rapidly increases cytosolic calcium, and so does IL-33 to a smaller extent; the addition of IL-33 augments the calcium increase. SP-induced VEGF production involves calcium-dependent PKC isoforms, as well as the ERK and JNK MAPKs. Gene expression of IL-33 and histidine decarboxylase (HDC), an indicator of mast cell presence/activation, is significantly increased in affected and unaffected (at least 15 cm away from the lesion) psoriatic skin, as compared with normal control skin. Immunohistochemistry indicates that IL-33 is associated with endothelial cells in both the unaffected and affected sites, but is stronger and also associated with immune cells in the affected site. These results imply that functional interactions among SP, IL-33, and mast cells leading to VEGF release contribute to inflammatory conditions, such as the psoriasis, a nonallergic hyperproliferative skin inflammatory disorder with a neurogenic component.
机译:肽物质P(SP)与炎症有关,例如牛皮癣,其中肥大细胞和VEGF增加。 SP和VEGF之间的关系尚未得到很好的研究,与促炎细胞因子,尤其是IL-33也没有任何相互作用。在这里我们报道SP(0.1-10μM)诱导人LAD2肥大细胞和人脐带血来源的培养的肥大细胞(hCBMCs)的基因表达和VEGF的分泌。通过在两种细胞类型中共同施用IL-33(5-100 ng / mL),可显着提高该效果。通过NK-1受体拮抗剂733,060的治疗抑制SP对VEGF释放的作用。 SP迅速增加了胞质钙,IL-33也在较小程度上增加。 IL-33的添加会增加钙的增加。 SP诱导的VEGF产生涉及钙依赖性PKC亚型,以及ERK和JNK MAPK。与正常对照皮肤相比,在受影响和未受影响(距病变至少15 cm)的牛皮癣皮肤中,IL-33和组氨酸脱羧酶(HDC)的基因表达显着增加,这是肥大细胞存在/激活的指标。免疫组织化学表明,IL-33在未受影响和受影响的部位均与内皮细胞有关,但强度更高,并且还与受影响部位的免疫细胞有关。这些结果暗示SP,IL-33和肥大细胞之间导致VEGF释放的功能性相互作用促成炎性病症,例如牛皮癣,一种具有神经源性成分的非过敏性过度增生性皮肤炎性疾病。

著录项

  • 来源
  • 作者单位

    Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Departments of Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111 Biochemistry Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111 Internal Medicine, Tufts University School of Medicine, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111 Allergy Clinical Research Center, Division of Allergology, Attikon General Hospital, Athens University Medical School, 12462 Athens, Greecern;

    Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Departments of Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111 Biochemistry Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111rn;

    Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Departments of Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111rn;

    Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Departments of Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111 Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Departments of Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111 Allergy Clinical Research Center, Division of Allergology, Attikon General Hospital, Athens University Medical School, 12462 Athens, Greecern;

    Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Departments of Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111rn;

    Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Departments of Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111;

    rn;

    Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Departments of Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111rn;

    Allergy Clinical Research Center, Division of Allergology, Attikon General Hospital, Athens University Medical School, 12462 Athens, Greecern;

    Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Departments of Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111rn;

    2nd Department of Dermatology, Attikon General Hospital, Athens University Medical School, 12462 Athens, Greecern;

    Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111rn;

    Department of Pharmacology, Boston University Medical School, Boston, MA 02118;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    inflammation; cytokines; IL-1; innate immunity; stress;

    机译:炎;细胞因子IL-1;先天免疫;强调;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号